Pfizer – a gold sponsor of the Joint Congress of ESPE and ESE 2025.
Pfizer is a global leader in biopharmaceutical innovation, dedicated to delivering breakthroughs that change patients’ lives. With nearly 4 decades of ongoing commitment to the growth hormone community, we have pioneered advancements in the treatment and long-term surveillance of growth hormone deficiency (GHD).1–3
Our research-driven therapies and patient support initiatives aim to address unmet needs and improve outcomes for children and adults living with GHD.
We’d love to hear from you! Come and join us at the Pfizer booth in Exhibition Hall E.
Congress activities
Monday 12 May 2025, 16:15–17:15 CEST, Room D2
Current perspectives in paediatric growth hormone deficiency (pGHD):
a spotlight on diagnosis, monitoring and long-term management
– A Pfizer-sponsored satellite symposium.
This symposium will provide data-driven, practical insights and current best practice in the management of paediatric patients with growth hormone deficiency.
Join our panel of world-class experts as they explore the latest thinking, trends and evidence in diagnostic approaches, monitoring strategies, and long-term treatment.
Welcome and introduction
Evolving paradigms in the diagnosis of pGHD
Prof. Marianna Rachmiel, Israel
Optimal monitoring of IGF-1 in pGHD to enhance treatment outcomes
Prof. Michel Polak, France
Long-term safety and outcomes in paediatric growth hormone therapy
Prof. Lars Sävendahl, Sweden
Panel discussion and closing remarks
This information is intended only for healthcare professionals.
1- Maniatis AK, et al. J Endocrincol Society. 2022;6(10):1–10.
2- Maghnie M, et al. J Clin Endocrinol Metab. 2022;107(12):3287–3301.
3- Geffner ME, et al. Ann Pediatr Endocrinol Metab. 2024;29(1):3–11.
PP-GEN-GLB-0538 | March 2025
